Pharmesis International (SGX:BFK) Total Equity: S$10.18 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGX:BFK Pharmesis International Ltd SGX:BFK
31 GF Score
Price S$0.11
GF Value S$0.09
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Pharmesis International Total Equity?

Pharmesis International SGX:BFK 31 Total Equity is S$10.18 Mil as of Dec. 2025. GuruFocus rates SGX:BFK with a GF Score™ of 31/100 and a GF Value™ of S$0.09 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Pharmesis International's total equity for the quarter that ended in Dec. 2025 was S$10.18 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Pharmesis International Total Equity Historical Data

* Premium members only.

The historical data trend for Pharmesis International's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmesis International Total Equity Chart

Pharmesis International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.87 11.05 10.11 11.42 10.18

Pharmesis International Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.11 9.83 11.42 10.75 10.18
SGX:BFK
31GF Score
Pharmesis International Ltd SGX:BFK
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmesis International Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Pharmesis International's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=17.543-7.364
=10.18

Pharmesis International's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=17.543-7.364
=10.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of S$10.18 Mil mean?
Pharmesis International (SGX:BFK) has a Total Equity of S$10.18 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Pharmesis International and its competitors.
Is Pharmesis International's Total Equity too high?
Pharmesis International's current Total Equity is S$10.18 Mil. Overall, Pharmesis International has a GF Score™ of 31/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmesis International's Total Equity compare to ZTS and UTHR?
Pharmesis International's Total Equity of S$10.18 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Pharmesis International and its competitors. Pharmesis International's current Total Equity is S$10.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmesis International stock overvalued right now?
Based on GuruFocus' analysis, Pharmesis International (SGX:BFK) is currently considered Modestly Overvalued. The stock's GF Value™ is S$0.09, compared to a current price of S$0.11 — trading 18.9% above its estimated fair value. The current Total Equity is S$10.18 Mil. Pharmesis International's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Pharmesis International (SGX:BFK), the current Total Equity is S$10.18 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmesis International (SGX:BFK) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmesis International stock appears to be overvalued. The current stock price of S$0.11 is trading 18.9% above its estimated GF Value™ of S$0.09. GuruFocus considers Pharmesis International to be Modestly Overvalued.

Key valuation signals for SGX:BFK:

  • Total Equity: S$10.18 Mil
  • GF Value™: S$0.09 vs. price of S$0.11 (18.9% above fair value)
  • GF Score™: 31/100 with 5 warning signs

No single metric tells the full story. See the SGX:BFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmesis International Business Description

Address 5 Kallang Sector, No. 03-02, Singapore, SGP, 349279
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs/TCH Procurement, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs/IP rental, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution, which derives maximum revenue, refers to agency products and internally manufactured products which are marketed through the distribution arm. The company derives revenue from the sale of medicines to domestic customers in China.
31GF Score

Get the complete analysis for SGX:BFK

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

S$0.11
Price
S$0.09
GF Value